PE20230856A1 - Proteinas de union restringidas activadas de forma condicional - Google Patents
Proteinas de union restringidas activadas de forma condicionalInfo
- Publication number
- PE20230856A1 PE20230856A1 PE2023000289A PE2023000289A PE20230856A1 PE 20230856 A1 PE20230856 A1 PE 20230856A1 PE 2023000289 A PE2023000289 A PE 2023000289A PE 2023000289 A PE2023000289 A PE 2023000289A PE 20230856 A1 PE20230856 A1 PE 20230856A1
- Authority
- PE
- Peru
- Prior art keywords
- domain
- restricted
- pseudovariable
- sdabd
- variable
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referida a una proteina de fusion que comprende, del extremo N al C: a) un primer sdABD que se une a HER2 (sdABD-HER2); b) un primer conector de dominio; c) un dominio Fv restringido que comprende: i) un primer dominio pesado variable que comprende una vhCDR1, vhCDR2 y vhCDR3; ii) un conector no escindible restringido (CNCL); y iii) un primer dominio ligero variable que comprende vlCDR1, vlCDR2 y vlCDR3; d) un segundo conector de dominio; e) un segundo sdABD-HER2; f) un conector escindible (CL); g) un dominio pseudo Fv restringido que comprende: i) un primer dominio ligero pseudovariable; ii) un conector no escindible (NCL); y iii) un primer dominio pesado pseudovariable; h) un tercer conector de dominio; y i) un tercer sdABD que se une a la seroalbumina humana (sdABDHSA); en el que el primer dominio pesado variable y el primer dominio ligero variable del dominio Fv restringido son capaces de unirse a CD3 humano pero el dominio pseudo Fv restringido no se une a CD3; el primer dominio pesado variable y el primer dominio ligero pseudovariable se asocian intramolecularmente para formar un Fv inactivo; y el primer dominio ligero variable y el primer dominio pesado pseudovariable se asocian intramolecularmente para formar un Fv inactivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066565P | 2020-08-17 | 2020-08-17 | |
| PCT/US2021/046217 WO2022040128A2 (en) | 2020-08-17 | 2021-08-17 | Constrained conditionally activated binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230856A1 true PE20230856A1 (es) | 2023-05-29 |
Family
ID=77655705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000289A PE20230856A1 (es) | 2020-08-17 | 2021-08-17 | Proteinas de union restringidas activadas de forma condicional |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240026011A1 (es) |
| EP (1) | EP4196503A2 (es) |
| JP (1) | JP2023538366A (es) |
| KR (1) | KR20230048146A (es) |
| CN (1) | CN116419925A (es) |
| AR (1) | AR123266A1 (es) |
| AU (1) | AU2021329290A1 (es) |
| CA (1) | CA3191431A1 (es) |
| CL (1) | CL2023000477A1 (es) |
| CO (1) | CO2023002164A2 (es) |
| EC (1) | ECSP23018458A (es) |
| IL (1) | IL300598A (es) |
| MX (1) | MX2023002002A (es) |
| PE (1) | PE20230856A1 (es) |
| TW (1) | TW202214707A (es) |
| WO (1) | WO2022040128A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342521A (zh) * | 2022-02-23 | 2023-11-01 | 日商武田藥品工業股份有限公司 | 條件性雙特異性結合蛋白 |
| WO2024040220A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding fusion proteins |
| WO2024040228A2 (en) * | 2022-08-19 | 2024-02-22 | Regents Of The University Of Minnesota | Cd83 binding proteins |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA118833C2 (uk) | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
| WO2017156178A1 (en) | 2016-03-08 | 2017-09-14 | Maverick Therapeutics, Inc. | Inducible binding proteins and methods of use |
| MX2020002667A (es) | 2017-09-08 | 2020-08-03 | Maverick Therapeutics Inc | Proteinas de unión condicionalmente activadas restringidas. |
| JP2022524338A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 拘束され、条件的に活性化された結合タンパク質 |
-
2021
- 2021-08-17 EP EP21766347.5A patent/EP4196503A2/en active Pending
- 2021-08-17 AR ARP210102304A patent/AR123266A1/es unknown
- 2021-08-17 JP JP2023511947A patent/JP2023538366A/ja active Pending
- 2021-08-17 MX MX2023002002A patent/MX2023002002A/es unknown
- 2021-08-17 TW TW110130298A patent/TW202214707A/zh unknown
- 2021-08-17 AU AU2021329290A patent/AU2021329290A1/en active Pending
- 2021-08-17 US US18/021,730 patent/US20240026011A1/en active Pending
- 2021-08-17 CA CA3191431A patent/CA3191431A1/en active Pending
- 2021-08-17 PE PE2023000289A patent/PE20230856A1/es unknown
- 2021-08-17 CN CN202180066644.9A patent/CN116419925A/zh active Pending
- 2021-08-17 WO PCT/US2021/046217 patent/WO2022040128A2/en active Application Filing
- 2021-08-17 KR KR1020237009028A patent/KR20230048146A/ko unknown
- 2021-08-17 IL IL300598A patent/IL300598A/en unknown
-
2023
- 2023-02-16 CL CL2023000477A patent/CL2023000477A1/es unknown
- 2023-02-27 CO CONC2023/0002164A patent/CO2023002164A2/es unknown
- 2023-03-16 EC ECSENADI202318458A patent/ECSP23018458A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23018458A (es) | 2023-04-28 |
| CN116419925A (zh) | 2023-07-11 |
| IL300598A (en) | 2023-04-01 |
| US20240026011A1 (en) | 2024-01-25 |
| CO2023002164A2 (es) | 2023-03-07 |
| AU2021329290A1 (en) | 2023-04-13 |
| KR20230048146A (ko) | 2023-04-10 |
| TW202214707A (zh) | 2022-04-16 |
| WO2022040128A3 (en) | 2022-04-07 |
| CL2023000477A1 (es) | 2023-11-10 |
| CA3191431A1 (en) | 2022-02-24 |
| AR123266A1 (es) | 2022-11-16 |
| EP4196503A2 (en) | 2023-06-21 |
| JP2023538366A (ja) | 2023-09-07 |
| MX2023002002A (es) | 2023-07-06 |
| WO2022040128A2 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230856A1 (es) | Proteinas de union restringidas activadas de forma condicional | |
| PE20212205A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
| PE20171324A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales | |
| PE20200717A1 (es) | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| PE20161431A1 (es) | Anticuerpos biespecificos que se unen a cd38 y cd3 | |
| AR085624A2 (es) | Anticuerpos de p-caderina | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| PE20120414A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
| CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| ECSP16070447A (es) | Moleculas de anticuerpo para tim-3 y sus usos | |
| PE20141995A1 (es) | Moleculas que son anticuerpos con especificidad por ox 40 humano | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CR20180365A (es) | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| NZ607510A (en) | Anti-il-1 beta antibodies and methods of use | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| AR083672A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| EA201100527A1 (ru) | Биологические продукты | |
| RU2011143905A (ru) | ПОЛИСПЕЦИФИЧНЫЕ АНТИТЕЛА, ВКЛЮЧАЮЩИЕ АНТИТЕЛА ПОЛНОЙ ДЛИНЫ И ОДНОЦЕПОЧЕЧНЫЕ ФРАГМЕНТЫ Fab | |
| AR078254A1 (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas |